Amgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar version of the blockbuster cancer infection biologic. Neulasta brought in $4.5 billion ...

As a result Neulasta was still Amgen’s second biggest selling drug last year, with the US accounting for nearly $3.9 billion in sales, with only $609 million coming from the rest of the world.

The Niopeg is comparable to the reference biologic drug Neulasta. Nora Pharma ... Niopeg will be available in Canada in a prefilled syringe containing 6mg/0.6ml. Sunshine Biopharma CEO Dr Steve ...

Is the Neulasta Market Poised for Significant Growth? The Neulasta market has experienced considerable expansion in recent years, with a strong historic compound annual growth rate (HCAGR). .The ...

In recent years, Cinfa Biotech used its resources to advance B12019, a biosimilar copy of Amgen’s chemotherapy-induced neutropenia drug Neulasta, through clinical trials. B12019 and Neulasta are ...